Novocure Q2 revenue up 6%, beats analyst estimates

NovoCure

24/07/2025 12:11

Overview

Novocure Q2 2025 revenue rises 6% yr/yr, beating analyst expectations

Company reports Q2 net loss of $40.1 mln, with EPS at $0.36

Gross margin declines to 74% due to new product rollout and tariffs

Outlook

Novocure plans PMA submission for pancreatic cancer treatment in Q3 2025

Company expects PMA submission for brain metastases from NSCLC in H2 2025

Topline data from PANOVA-4 trial expected in H1 2026

Topline data from TRIDENT trial expected in H1 2026

Result Drivers

PATIENT GROWTH - Revenue increase driven by growth in active patient numbers across major markets

PRODUCT LAUNCHES - Gross margin decline attributed to new product rollout and increased tariffs

EXPENSES - Higher costs in research, development, and sales due to clinical trial ramp-ups and NSCLC sales force expansion

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$158.80 mln
$154.20 mln (8 Analysts)
Q2 EPS
$0.36
Q2 Net Income
-$40.14 mln
Q2 Gross Profit
$117.33 mln
Q2 Operating Income
-$39.52 mln
Q2 Pretax Profit
-$34.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Novocure Ltd is $33.00, about 50% above its July 23 closing price of $16.51

Press Release: ID:nBw6B75nqa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)